KRAS and RAS inhibitor trial starts

RecordSTO-56S6BAAHKS-RYQHT8XX68-MG83TJ

226

Global · 1 Jan 2023 to 27 Sep 2026

KRAS and RAS inhibitor trial starts worldwide were 226 between 1 January 2023 and 27 September 2026 (ClinicalTrials.gov).

Original source

Publisher: ClinicalTrials.gov
Authority tier: T1 Official
Report: ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country
Locator: totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country.
Retrieved: 27 Sep 2026
Status: Verified

What the source says

{"totalCount":226,"studies":[
ClinicalTrials.gov (U.S. National Library of Medicine), ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country, totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country.

Checked: the figure 226 is stated in this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

APA

ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_56S6BAAHKSRYQHT8XX68MG83TJ

Other formats: MLA, Chicago, BibTeX

MLA: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country." 2026, https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_56S6BAAHKSRYQHT8XX68MG83TJ.
Chicago: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country." 2026. https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib%20OR%20adagrasib%20OR%20divarasib%20OR%20daraxonrasib%20OR%20RMC-6236%20OR%20elironrasib%20OR%20RMC-6291%20OR%20zoldonrasib%20OR%20RMC-9805%20OR%20olomorasib%20OR%20garsorasib%20OR%20fulzerasib%20OR%20glecirasib%20OR%20MRTX1133%20OR%20%22KRAS%20G12C%20inhibitor%22%20OR%20%22KRAS%20G12D%20inhibitor%22%20OR%20%22pan-KRAS%22%20OR%20%22pan-RAS%22%20OR%20%22KRAS%20inhibitor%22%20OR%20opnurasib%20OR%20D-1553%20OR%20LY3537982%20OR%20HRS-4642%20OR%20INCB161734%20OR%20ASP3082%20OR%20setidegrasib%20OR%20%22AMG%20510%22%20OR%20MRTX849%20OR%20GDC-6036%20OR%20G12D%20OR%20GFH925%20OR%20IBI351%20OR%20JAB-21822&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_56S6BAAHKSRYQHT8XX68MG83TJ.
BibTeX: @misc{clinicaltrialsgo2026ctgovmg83tj, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_56S6BAAHKSRYQHT8XX68MG83TJ}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=sotorasib\%20OR\%20adagrasib\%20OR\%20divarasib\%20OR\%20daraxonrasib\%20OR\%20RMC-6236\%20OR\%20elironrasib\%20OR\%20RMC-6291\%20OR\%20zoldonrasib\%20OR\%20RMC-9805\%20OR\%20olomorasib\%20OR\%20garsorasib\%20OR\%20fulzerasib\%20OR\%20glecirasib\%20OR\%20MRTX1133\%20OR\%20\%22KRAS\%20G12C\%20inhibitor\%22\%20OR\%20\%22KRAS\%20G12D\%20inhibitor\%22\%20OR\%20\%22pan-KRAS\%22\%20OR\%20\%22pan-RAS\%22\%20OR\%20\%22KRAS\%20inhibitor\%22\%20OR\%20opnurasib\%20OR\%20D-1553\%20OR\%20LY3537982\%20OR\%20HRS-4642\%20OR\%20INCB161734\%20OR\%20ASP3082\%20OR\%20setidegrasib\%20OR\%20\%22AMG\%20510\%22\%20OR\%20MRTX849\%20OR\%20GDC-6036\%20OR\%20G12D\%20OR\%20GFH925\%20OR\%20IBI351\%20OR\%20JAB-21822\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\%20AND\%20AREA\%5BStartDate\%5DRANGE\%5B2023-01-01\%2C2026-09-27\%5D\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }

Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Primary source

Publisher: ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
Authority tier: Tier 1 · Multilateral Official
Report: ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country
Type: Dataset
Published: —
Locator: totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country.
Retrieved: 27 September 2026
Link status: Reachable (HTTP 200)
Report licence: Public domain

Verification

Status: Verified
Review protocol: pipeline:ctgov-api-totalcount-verified
Checked on: 27 September 2026
Last revision: 27 September 2026
Permanent URL: /stat/stat_56S6BAAHKSRYQHT8XX68MG83TJ

Same indicator, other countries

1 Jan 2023 to 27 Sep 2026 figures for the same indicator, ranked highest first.

Country or region	Value	Source	Details
United States	116	ClinicalTrials.gov	Open record
China	91	ClinicalTrials.gov	Open record
United States	25	ClinicalTrials.gov	Open record
China	16	ClinicalTrials.gov	Open record

This figure in context

Cited in

KRAS and RAS inhibitors: after G12C, the race moves to G12D and pan-RAS

Go further

Record last modified 27 September 2026. Value type: actual. Update cadence: irregular. This page is permanently addressable at statorigin.org/stat/stat_56S6BAAHKSRYQHT8XX68MG83TJ.